Gwen Nichols, MD, on Hematologic Cancers, Emerging Treatments, and the LLS - Cancer Therapy Advisor

Gwen Nichols, MD, on Hematologic Cancers, Emerging Treatments, and the LLS

Chapter 1

The Future Focus of LLS Research

Gwen Nichols, MD, chief medical officer of the Leukemia & Lymphoma Society (LLS), discusses how she is directing the LLS’s research focus.

Chapter 2

MDM2: A Therapeutic Target?

Gwen Nichols, MD, chief medical officer of the Leukemia & Lymphoma Society (LLS), discusses the potential of targeting MDM2 for hematologic cancers.

Chapter 3

p53 Dysregulation: Causes and Effects

Gwen Nichols, MD, chief medical officer of the Leukemia & Lymphoma Society (LLS), discusses the role of p53 in oncogenesis and the proliferation of various cancers.

Chapter 4

Combination Therapies for Multiple Myeloma

Gwen Nichols, MD, chief medical officer of the Leukemia & Lymphoma Society (LLS), discusses the complexity and potential of the many possible treatment combinations now available for patients with multiple myeloma.

Chapter 5

The Future of Treating Hematologic Cancers

Gwen Nichols, MD, chief medical officer of the Leukemia & Lymphoma Society (LLS), discusses how the treatment of hematologic cancers is likely to change, including the roles biomarkers and epigenetics are likely to play in personalized care.